Valuation: hVIVO plc

Market Cap 46.03M 62.13M 53.85M 50.48M 86.61M 5.93B 88M 594M 232M 2.97B 233M 228M 9.9B P/E 2026 *
-13.5x
P/E 2027 * -102x
Enterprise Value 37.54M 50.67M 43.92M 41.17M 70.63M 4.84B 71.76M 485M 189M 2.42B 190M 186M 8.07B EV / Sales 2026 *
0.75x
EV / Sales 2027 * 0.65x
Free-Float
96.84%
Yield 2026 *
0.48%
Yield 2027 * 1.21%
1 week-2.90%
Current month-9.46%
1 month-2.19%
3 months-9.46%
6 months-21.18%
Current year+6.35%
1 week 6.5
Extreme 6.5044
7.1
1 month 6.33
Extreme 6.33
7.9
Current year 5.32
Extreme 5.322
11
1 year 4.3
Extreme 4.305
11
3 years 4.3
Extreme 4.305
32
5 years 4.3
Extreme 4.305
32
10 years 4.3
Extreme 4.305
48
Manager TitleAgeSince
Chief Executive Officer 57 2022-02-23
Corporate Officer/Principal 39 2017-06-30
Director of Finance/CFO 63 2022-10-17
Director TitleAgeSince
Chairman 65 2025-06-04
Director/Board Member 57 2021-10-12
Director/Board Member 63 2022-10-17
Date Insider Type Main position Quantity % Market Cap.
12/15/25 Buy

Chief Financial Officer

520,000 0.0757%
12/15/25 Buy

Chief Executive Officer

3,310,405 0.4819%
6/2/25 Buy

Chief Financial Officer

683,232 0.0995%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.90%-37.67%-61.71% 62.17M
+1.17%+1.09%+4.03%+15.90% 48.72B
-1.71%+2.35%+461.27%+574.83% 43.99B
-0.75%+7.97%+15.80%+74.44% 40.82B
+0.09%+3.72%+26.73%+9.52% 39.79B
0.00%+6.15%+23.03%+48.00% 32.7B
-1.47%+0.29%+25.37%+120.88% 16.66B
-3.57%-1.13% - - 16.84B
+0.72%+0.31%+4.94%+21.57% 13.95B
-0.70%+6.11%+81.77%+29.89% 13.58B
Average -0.61%+2.98%+67.25%+92.59% 26.71B
Weighted average by Cap. -0.47%+3.66%+98.10%+134.93%

Financials

2026 *2027 *
Net sales 50.37M 67.98M 58.93M 55.24M 94.77M 6.49B 96.29M 650M 254M 3.25B 255M 250M 10.83B 55.23M 74.55M 64.62M 60.58M 104M 7.11B 106M 713M 278M 3.56B 280M 274M 11.88B
Net income -3.49M -4.71M -4.09M -3.83M -6.57M -450M -6.68M -45.09M -17.6M -225M -17.69M -17.31M -751M -1.03M -1.38M -1.2M -1.12M -1.93M -132M -1.96M -13.24M -5.17M -66.12M -5.2M -5.08M -221M
Net Debt -8.49M -11.46M -9.93M -9.31M -15.98M -1.09B -16.23M -110M -42.81M -548M -43.03M -42.1M -1.83B -9.93M -13.41M -11.62M -10.89M -18.69M -1.28B -18.99M -128M -50.08M -641M -50.34M -49.25M -2.14B
Logo hVIVO plc
hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.
Employees
376
Date Price Change Volume
26-08-13 GBX 6.700 0.00% 1,403,779
26-08-12 GBX 6.700 -2.90% 1,471,363
26-08-11 GBX 6.900 +0.73% 1,270,812
26-08-10 GBX 6.850 -0.72% 2,021,816
26-08-07 GBX 6.900 0.00% 847,701
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
0.0670GBP
Average target price
0.1731GBP
Spread / Average Target
+158.39%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VENN Stock